Cargando…

Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation

Cytomegalovirus (CMV) infection negatively influences both short- and long-term outcomes after cardiothoracic transplantation. In heart transplantation, registry analyses have shown that CMV immunoglobulin (CMVIG) with or without virostatic prophylaxis is associated with a significant reduction in m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rea, Federico, Potena, Luciano, Yonan, Nizar, Wagner, Florian, Calabrese, Fiorella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Supplement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764018/ https://www.ncbi.nlm.nih.gov/pubmed/26900991 http://dx.doi.org/10.1097/TP.0000000000001096

Ejemplares similares

Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview
por: Grossi, Paolo, et al.
Publicado: (2016)

CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients
por: Schulz, Uwe, et al.
Publicado: (2016)

The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV
por: Carbone, Javier
Publicado: (2016)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

1198. Measurement of Pre-transplant Anti-cytomegalovirus (CMV) Immunoglobulin G Titer to Predict Risk of CMV Infection in CMV-seropositive Kidney Transplant Recipients
por: Kirisri, Similan, et al.
Publicado: (2020)

Intrathecal cytomegalovirus immunoglobulin for CMV encephalitis post allogeneic stem cell transplantation
por: Pang, Ian, et al.
Publicado: (2022)

1747. Impact of Inappropriately Low Cytomegalovirus (CMV) Prophylaxis Dosing on CMV Outcomes Among Lung Transplant (LT) Recipients
por: Watts, Corey, et al.
Publicado: (2019)

Evaluation of Two Different CMV-Immunoglobulin Regimens for Combined CMV Prophylaxis in High-Risk Patients following Lung Transplant
por: Mora, Víctor M., et al.
Publicado: (2022)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

604 Risk Factors for Cytomegalovirus (CMV) Reactivation in CMV-seropositive Liver Transplant Patients
por: Bruminhent, Jackrapong, et al.
Publicado: (2014)

Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients
por: McBride, Jacqueline M, et al.
Publicado: (2019)

454 Cytomegalovirus (CMV) Disease after Lung Transplantation (LT) is associated with increased mortality despite Extended Antiviral Prophylaxis
por: Beam, Elena, et al.
Publicado: (2014)

Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
por: Dieamant, Débora C, et al.
Publicado: (2013)

Thrombosis Associated With Cytomegalovirus (CMV) in a Kidney Transplant Recipient
por: Wang, Lin, et al.
Publicado: (2021)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients
por: Lee, Hyeyoung, et al.
Publicado: (2017)

Cytomegalovirus (CMV) Infection and Latency
por: O’Connor, Christine M.
Publicado: (2021)

1380. Real-world Effectiveness and Complications of Valganciclovir (VGC) Prophylaxis for Kidney Transplant (KT) Recipients at High Risk for Cytomegalovirus (CMV) infection (CMV Donor (D)+/Recipient (R)-)
por: Roumpz, Caroline G, et al.
Publicado: (2021)

Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant
por: Kim, Taeeun, et al.
Publicado: (2020)

Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
por: He, Ran, et al.
Publicado: (2011)

Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation
por: Wang, Xiaodong, et al.
Publicado: (2021)

Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
por: Lodding, I P, et al.
Publicado: (2018)

Protective Cytomegalovirus (CMV)-Specific T-Cell Immunity Is Frequent in Kidney Transplant Patients without Serum Anti-CMV Antibodies
por: Litjens, Nicolle H. R., et al.
Publicado: (2017)

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia
por: Piñana, José Luis, et al.
Publicado: (2019)

CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins
por: Vassallo, Francesco, et al.
Publicado: (2020)

1597. Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients
por: Khurana, Mark Poulsen, et al.
Publicado: (2018)

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
por: Zamora, Danniel, et al.
Publicado: (2021)

1538. High Mortality of Cytomegalovirus (CMV) Pneumonia in Hematopietic Cell Transplant Recipients
por: Batista, Marjorie, et al.
Publicado: (2018)

Stimulatory Effect of CMV Immunoglobulin on Innate Immunity and on the Immunogenicity of CMV Antigens
por: Deml, Ludwig, et al.
Publicado: (2021)

Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
por: Nair, Smita K, et al.
Publicado: (2013)

Cytomegalovirus (CMV) seroprevalence in the adult population of Germany
por: Lachmann, Raskit, et al.
Publicado: (2018)

Acute Cytomegalovirus (CMV) Hepatitis in an Immunocompetent Adult
por: Zahid, Maleeha, et al.
Publicado: (2020)

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Marty, Francisco M, et al.
Publicado: (2018)

THE PREVALENCE OF CYTOMEGALOVIRUS (CMV) VIRURIA AMONG HOSPITALIZED CHILDREN AND THE RISK OF CMV ACQUISITION BY NURSES
por: Adler, Stuart P, et al.
Publicado: (1984)

Treatment of Cytomegalovirus Infection with Cidofovir and CMV Immune Globulin in a Lung Transplant Recipient
por: Wilkens, Heinrike, et al.
Publicado: (2016)

1079. The Risk of Cytomegalovirus (CMV) Infection and Recurrence Among Solid Organ Transplant Recipients
por: Reekie, Joanne, et al.
Publicado: (2020)

Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies
por: Han, Sang Hoon
Publicado: (2017)

Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation: A PRISMA-compliant article
por: Ruan, Yashi, et al.
Publicado: (2019)

2696. Impact of an Ultrasensitive Cytomegalovirus (CMV) Quantitative Nucleic Acid Test (qNAT) on CMV Detection and Therapy in Renal Transplant Recipients
por: Beechar, Vivek, et al.
Publicado: (2023)

CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab
por: Gambardella, Alessio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_edoeg2mn2bp9nbu99ksvt0ii90